Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.34 |
| ▸ | DNER | Q8NFT8 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 3/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.33 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | PRF1 | P14222 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | TSPO | P30536 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21914872 | 0.84 | BRD4 (0.37) | BRD4DNERBRD2BRD3BRDT | |
| SCHEMBL21591796 | 0.78 | TSHR (0.41) | BRD4DNERBRD2BRD3BRDT | |
| SCHEMBL23348743 | 0.76 | CHRM1 (0.43) | BRD4DNERADORA3TSPO | |
| SCHEMBL9284918 | 0.76 | RECQL (0.37) | BRD4DNERADORA3TSPO | |
| SCHEMBL23810818 | 0.76 | CHRM1 (0.43) | BRD4DNERADORA3TSPO | |
| SCHEMBL22271629 | 0.76 | CHRM1 (0.41) | BRD4 | |
| SCHEMBL9284742 | 0.72 | RECQL (0.43) | BRD4DNERADORA3TSPO | |
| SCHEMBL7479638 | 0.71 | CDK2 (0.47) | BRD4ADORA3TSPO | |
| SCHEMBL22271630 | 0.71 | BRD4 (0.38) | BRD4DNER | |
| SCHEMBL19986334 | 0.70 | BRD4 (0.40) | BRD4DNERADORA3TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708374-B2 | Preparation of condensed triazepine derivatives and their use as BET inhibitors | Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) | 2023-07-25 | — | — | US | disclosed |
| US-11708374-B2 | Preparation of condensed triazepine derivatives and their use as BET inhibitors | Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) | 2023-07-25 | — | — | US | disclosed |
| US-11708374-B2 | Preparation of condensed triazepine derivatives and their use as BET inhibitors | Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) | 2023-07-25 | — | — | US | disclosed |
| EP-3806860-A1 | PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS | Dybly AG (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-20210101909-A1 | PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS | Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) | 2021-04-08 | — | — | US | disclosed |
| US-20210101909-A1 | PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS | Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) | 2021-04-08 | — | — | US | disclosed |
| CN-112312916-A | Preparation of condensed triazepine derivatives and their use as BET inhibitors | 戴布里股份公司 | 2021-02-02 | — | — | CN | disclosed |
| US-10906917-B2 | Preparation of condensed triazepine derivatives and their use as BET inhibitors | DYBLY AG (CH) | 2021-02-02 | — | — | US | disclosed |
| US-10906917-B2 | Preparation of condensed triazepine derivatives and their use as BET inhibitors | DYBLY AG (CH) | 2021-02-02 | — | — | US | disclosed |
| US-20200231598-A1 | PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS | Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) | 2020-07-23 | — | — | US | disclosed |
| US-20200231598-A1 | PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS | Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) | 2020-07-23 | — | — | US | disclosed |
| WO-2019238557-A1 | PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS | DYBLY AG (CH) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019238557-A1 | PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS | DYBLY AG (CH) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708374-B2 | Preparation of condensed triazepine derivatives and their use as BET inhibitors | BET1, EP300, BICRA | BRD4 4/4885DNER 1399/4885BRD2 20/4885 |
| US-20210101909-A1 | PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS | BET1, EP300, BICRA | BRD4 4/4885DNER 1399/4885BRD2 20/4885 |
| US-10906917-B2 | Preparation of condensed triazepine derivatives and their use as BET inhibitors | BET1, EP300, BICRA | BRD4 4/4885DNER 1399/4885BRD2 20/4885 |
| US-20200231598-A1 | PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS | BET1, EP300, BICRA | BRD4 4/4885DNER 1399/4885BRD2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.